Anadis Limited   Overview Research driven public biotechnology company (ASX:ANX) Polyclonal dairy-derived antibodies against: Areas of focus: Infectious diseases Auto-immune diseases Cancer Rapid, high volume method of harvesting Proprietary and patented technology and products Oral & respiratory delivery routes Fast, low-cost cycle from bench to market Immediate high value targets available addressing markets in excess of $30 billion. Business Opportunities (i.e Corporate Alliances/Partnerships) The company is seeking distributors, agents, in-licensing companies, to distribute and market our range of primary milking, hyperimmune colostrum antibody products to pharmacy and health care providers internationally. Technology/Products and Services Description Hyperimmune colostrum development Hyperimmune colostrum primary milking collection Supply of finished products Supply of raw materials (actives) Indications of products: Reduction in the risk of E.coli caused diarrhoea (Travellers’ Diarrhoea) Prevention of Rotavirus caused diarrhoea in children Relief from the symptoms H.pylori infection Relief from the symptoms of gastrointestinal disorders Protection against Enterovirus 71 (hand foot and mouth disease) Competitive Advantages Rapid bench to market Active raw materials are recognised as safe for use orally Cost effective method to harvest polyclonal antibodies from first-milking of immunised cow   Rapid development, manufacturing and regulatory pathway for use in new indications Proprietary proven platform technology: viruses, bacteria and toxins Website address: www.anadis.com